5-year results of a newly implemented mechanical circulatory support program for terminal heart failure patients in a Swiss non-cardiac transplant university hospital.
Comprehensive heart-failure center
Destination therapy
Left ventricular assist device
Journal
Journal of cardiothoracic surgery
ISSN: 1749-8090
Titre abrégé: J Cardiothorac Surg
Pays: England
ID NLM: 101265113
Informations de publication
Date de publication:
31 Mar 2021
31 Mar 2021
Historique:
received:
27
10
2020
accepted:
19
03
2021
entrez:
1
4
2021
pubmed:
2
4
2021
medline:
29
6
2021
Statut:
epublish
Résumé
In Switzerland, long-term circulatory support programs have been limited to heart transplant centers. In 2014, to improve the management of patients with end-stage heart failure not eligible for transplantation, we implemented a left ventricular assist device (LVAD) program for destination therapy at the University Hospital of Basel. We described the program set-up with practical aspects. Patients aged 65 and above with therapy refractory end-stage heart failure without major contraindication for LVAD implantation were included. Younger patients with bridge-to-candidacy profile were also considered. Using the Kaplan-Meier estimate, we retrospectively analyzed the overall survival and freedom from major adverse events after LVAD implantation. We compared our results to internationally reported data. Between October 2014 and September 2019, 16 patients received an LVAD in our center. The mean age at implantation was 67.1 years. The mean EuroSCORE II was 24.4% and the median INTERMACS level was 4. Thirteen patients received an LVAD as destination therapy and three patients as bridge-to-candidacy. The overall survival was 87.5 and 70% at 1 and 2 years, respectively. Freedom from stroke was 81.3% at 1 and 2 years. Freedom from device infection was 67.7 and 58.7% at 1 and 2 years, respectively. Freedom from gastrointestinal bleeding was 75 and 56.3% at 1 and 2 years, respectively. Freedom from readmission was 50 and 31.3% and at 6 months and 1 year, respectively. The Basel experience demonstrated the possible implementation of an LVAD program for destination therapy or bridge-to-candidacy in a non-transplant comprehensive heart-failure center with midterm survival results and freedom from major adverse events comparable to international registries. Patient selection remains crucial. This study was registered on the ClinicalTrials.gov database ( NCT04263012 ).
Sections du résumé
BACKGROUND
BACKGROUND
In Switzerland, long-term circulatory support programs have been limited to heart transplant centers. In 2014, to improve the management of patients with end-stage heart failure not eligible for transplantation, we implemented a left ventricular assist device (LVAD) program for destination therapy at the University Hospital of Basel.
METHODS
METHODS
We described the program set-up with practical aspects. Patients aged 65 and above with therapy refractory end-stage heart failure without major contraindication for LVAD implantation were included. Younger patients with bridge-to-candidacy profile were also considered. Using the Kaplan-Meier estimate, we retrospectively analyzed the overall survival and freedom from major adverse events after LVAD implantation. We compared our results to internationally reported data.
RESULTS
RESULTS
Between October 2014 and September 2019, 16 patients received an LVAD in our center. The mean age at implantation was 67.1 years. The mean EuroSCORE II was 24.4% and the median INTERMACS level was 4. Thirteen patients received an LVAD as destination therapy and three patients as bridge-to-candidacy. The overall survival was 87.5 and 70% at 1 and 2 years, respectively. Freedom from stroke was 81.3% at 1 and 2 years. Freedom from device infection was 67.7 and 58.7% at 1 and 2 years, respectively. Freedom from gastrointestinal bleeding was 75 and 56.3% at 1 and 2 years, respectively. Freedom from readmission was 50 and 31.3% and at 6 months and 1 year, respectively.
CONCLUSIONS
CONCLUSIONS
The Basel experience demonstrated the possible implementation of an LVAD program for destination therapy or bridge-to-candidacy in a non-transplant comprehensive heart-failure center with midterm survival results and freedom from major adverse events comparable to international registries. Patient selection remains crucial.
TRIAL REGISTRATION
BACKGROUND
This study was registered on the ClinicalTrials.gov database ( NCT04263012 ).
Identifiants
pubmed: 33789723
doi: 10.1186/s13019-021-01447-5
pii: 10.1186/s13019-021-01447-5
pmc: PMC8011141
doi:
Banques de données
ClinicalTrials.gov
['NCT04263012']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
64Références
Ann Thorac Surg. 2013 Sep;96(3):857-63; discussion 863-4
pubmed: 23791165
Circulation. 2012 Nov 27;126(22):2648-67
pubmed: 23109468
Ann Thorac Surg. 2020 Mar;109(3):649-660
pubmed: 32115073
N Engl J Med. 2018 Apr 12;378(15):1386-1395
pubmed: 29526139
Eur J Heart Fail. 2017 May;19(5):595-602
pubmed: 28198133
Neth Heart J. 2015 Feb;23(2):102-8
pubmed: 25273921
J Heart Lung Transplant. 2011 Aug;30(8):849-53
pubmed: 21530318
Eur J Cardiothorac Surg. 2018 Feb 1;53(2):309-316
pubmed: 29029117
ESC Heart Fail. 2016 Mar;3(1):26-34
pubmed: 27774264
Cardiol Rev. 2019 Jan/Feb;27(1):8-13
pubmed: 30520778
Ann Thorac Surg. 1993 Jan;55(1):276-82
pubmed: 8417700
J Heart Lung Transplant. 2017 Oct;36(10):1080-1086
pubmed: 28942782
Eur J Cardiothorac Surg. 2020 Sep 1;58(3):511-518
pubmed: 32236472
N Engl J Med. 2001 Nov 15;345(20):1435-43
pubmed: 11794191
JACC Heart Fail. 2015 Oct;3(10):818-28
pubmed: 26450000
Eur Heart J. 2016 Jul 14;37(27):2129-2200
pubmed: 27206819
Artif Organs. 2014 Jul;38(7):543-8
pubmed: 24392937
J Thorac Dis. 2018 Jun;10(Suppl 15):S1743-S1750
pubmed: 30034847
J Thorac Dis. 2018 Jun;10(Suppl 15):S1758-S1762
pubmed: 30034849
N Engl J Med. 2017 Feb 2;376(5):451-460
pubmed: 28146651
Open Forum Infect Dis. 2020 Apr 17;7(5):ofaa124
pubmed: 32405511
Dig Dis Sci. 1984 Jun;29(6):481-5
pubmed: 6609803
Circulation. 2012 Jun 26;125(25):3191-200
pubmed: 22619284
Swiss Med Wkly. 2014 Nov 06;144:w14057
pubmed: 27922169
J Thorac Dis. 2018 Jun;10(Suppl 15):S1751-S1757
pubmed: 30034848
J Am Coll Cardiol. 2008 Jun 3;51(22):2163-72
pubmed: 18510965
Circ Heart Fail. 2009 Jan;2(1):3-10
pubmed: 19808309
J Card Surg. 2020 Feb;35(2):383-389
pubmed: 31808964
Ann Thorac Surg. 2010 Oct;90(4):1270-7
pubmed: 20868826